Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases

Journal of Neural Transmission

Volumn 111, Issue 10-11, 2004, Pages 1455-1471

  Youdim, M B H ^a   Fridkin, M ^b   Zheng, H ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Dopamine neuron degeneration; Iron; Iron chelators; Lazaroids; MAO A and MAO B inhibition; Oxidative stress; Parkinson's disease; Reactive oxygen species; VK 28

Indexed keywords

1,10 PHENANTHROLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE; DEFEROXAMINE; FLAVOPROTEIN; HYDROXYL RADICAL; LAZAROID; METAL CHELATE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; OXIDOPAMINE; PENICILLAMINE; RASAGILINE; REACTIVE OXYGEN METABOLITE; TIRILAZAD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOOXIDATION; BLOOD BRAIN BARRIER; BRAIN MITOCHONDRION; CELLULAR IMMUNITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG POTENCY; DRUG TARGETING; ENZYME INHIBITION; IRON CHELATION; LIPID PEROXIDATION; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; INDANS; IRON CHELATING AGENTS; MALE; MITOCHONDRIA; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARGYLINE; PARKINSON DISEASE; PIPERAZINES; PROPYLAMINES; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 7944235232     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0143-x     Document Type: Article

References (76)

1. Bar Am O, Amit T, Youdim MBH (2004a) Contrasting neuroprotective and neurotoxic actions of respective metabolites of antiparkinson drugs rasagiline and selegiline. Neurosci Lett 355: 169-172
2. Bar Am O, Yogev-Falch M, Amit T, Sagi Y, Youdim MBH (2004b) Regulation of amyloid precursor protein and protein kinase C functional machinery by the anti-parkinson drug, rasagiline and its derivatives, in vivo. J Neurochem (in press)
3. Ben-Shachar D, Eshel G, Finberg JP, Youdim MB (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444
4. Ben Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46(2): 254-263
5. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2000) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64(5-6): 1037-1048
6. Bharath S, Hsu M, Kaur D, et al. (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64: 1037-1048
7. Binda C, Hubalek F, Li M, et al. (2004) Crystal structure of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J Med Chem 47: 1767-1774
8. Birkmayer W, Riederer P, Youdim MB, Linauer W (1975) The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm 36: 303-326
9. Borisenko GG, Kagan VE, Hsia CJ, Schor NF (2000) Interaction between 6-hydroxydopamine and transferrin: "Let my iron go". Biochemistry 39: 3392-3400
10. Bradford MM (1976) A rapid and sensitive method for the quantitation of microquantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248
11. Braughler JM, Burton PS, Chase RL, Pregenzer JF, Jacobsen EJ, VanDoornik FJ, Tustin JM, Ayer DE, Bundy GL (1988) Novel membrane localized iron chelators as inhibitors of iron-dependent lipid peroxidation. Biochem Pharmacol 37(20): 3853-3860
12. Bush AI (2002) Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23(6): 1031-1038
13. Cesura AM, Muggli-Maniglio D, Lang G, Imhof R, Da Prada M (1990) Monoamine oxidase inhibition by moclobemide and 2-amino-ethyl carboxamide derivatives: mode of action and kinetic characteristics. J Neural Transm [Suppl] 32: 165-170
14. Cohen G (2000) Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 899: 112-120
15. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI (2000) Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci 920: 292-304
16. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989a) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52: 1830-1836
17. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989b) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52: 381-389
18. Double KL, Jellinger K, Zecca L, Youdim MBH, Riederer P, Gerlach M (2003) Iron neuromelanin and alpha-synuclein in beuropathogenesis of Parkinson's disease. In: Zatta P (ed) Metals ions in neurodegenerative disorders. World Scientific, New Jersey, pp 343-364
19. Edmondson DE, Binda C, Mattevi A (2004) The FAD binding sites of human monoamine oxidases A and B. Neurotoxicology 25(1-2): 63-72
20. Faucheux BA, Martin ME, Beumount C, Hauw JJ, Agid Y, Hirsch EC (2003) Increased redox activity of neuromelanin in the substantia nigra of parkinsonian patients. J Neurochem 86: 1142-1148
21. Gassen M, Youdim MBH (1997) The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 80: 159-166
22. Gassen M, Glinka Y, Pinchasi B, et al. (1996) Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur J Pharmacol 308: 219-225
23. 2 and 6-hydroxydopamine. Mov Disord 13: 242-248
24. Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 793: 793-807
25. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res 5(1-2): 35-44
26. Gluck MR, Krueger MJ, Ramsay RR, Sablin SO, Singer TP, Nicklas WJ (1994) Characterization of the inhibitory mechanism of 1-methyl-4-phenylpyridinium and 4-phenylpyridine analogs in inner membrane preparations. J Biol Chem 269(5): 3167-3174
27. Grunblatt E, Mandel S, Maor G, et al. (2001) Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal doamine neuronal loss. J Neurochem 77: 146-156
28. Hall S, Rutledge JN, Schauert T (1992) MRI, brain iron and experimental Parkinson's disease. J Neurol Sci 113: 198-208
29. Halliwell B (2001) Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716
30. Hubalek F, Binda C, Li M, et al. (2004) Inactivation of purified human recombinant monoamine oxidase A and B by rasagiline and ist analogues. J Med Chem 47: 1760-1766
31. Janssens de Varebeke P, Pauwels G, Buyse C, David-Remacle M, De Mey J, Roba J, Youdim MB (1989) The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B. J Neurochem 53(4): 1109-1116
32. Jellinger KA (1999) The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140
33. Jellinger K, Paulus W, Grundke-Iqbal I, et al. (1990) Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm (PD Sect) 2: 327-340
34. Jellinger K, Kienzl E, Rumpelmair G, et al. (1992) Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 59: 1168-1171
35. Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47: S161-S170
36. Kaur D, Yantiri F, Rajagopalan S, et al. (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909
37. Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104: 469-481
38. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MBH (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1316: 160-168
39. Levites Y, Weinreb O, Maor G, et al. (2001) Green tea polyphenol (-)-Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78: 1073-1082
40. Lode HN, Bruchelt G, Rieth AG, Niethammer D (1990) Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Radic Res Commun 11: 153-158
41. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB (2003) Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17(10): 729-762
42. Maruyama W, Naoi M (1999) Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 111: 189-200
43. Maruyama W, Youdim MBH, Naoi M (2001a) Antiapoptotic function of N-propargylamine-1(R)- and (S)-aminoindan, Rasagiline and TV1022. Ann NY Acad Sci 939: 320-329
44. Melamed E, Youdim MBH (1985) In vivo effect of MPTP on monoamine oxidase activity in mouse striatum. Brain Res 359: 360-364
45. Miyajima H, Takahashi Y, Kamata T, Shimizu H, Sakai N, Gitlin JD (1997) Use of desferrioxamine in the treatment of aceruloplasminemia. Ann Neurol 41: 404-407
46. Naoi M, Maruyama W, Akao Y, Yi H (2002) Mitochondria determine the survival and death in apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, and neuroprotection by propargylamines. J Neural Transm 109: 607-621
47. Oreland L, Gottfries CG (1986) Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type. Prog Neuropsychopharmacol Biol Psychiatry 10(3-5): 533-534
48. Parkinson Study Group (1989) Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 321(20): 1364-1371
49. Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328(3): 176-183
50. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59(12): 1937-1943
51. Ren MQ, Ong WY, Wang XS, Watt F (2003) A nuclear microscopic and histological study of iron concentrations and distribution in ther mid brain of two age groups of monkeys unilaterally injected with MPTP. Exp Neurol 184: 947-954
52. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520
53. Shoham S, Youdim MBH (2000) Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol 46: 743-760
54. Smith MA, Perry G (1995) Free radical damage, iron, and Alzheimer's disease. J Neurol Sci 134 [Suppl]: 92-94
55. Sofic E, Riederer P, Heinsen H, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MBH (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199-205
56. Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, Tatton NA (2002) Propargylamines induce anti-apoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301: 753-764
57. Tatton W, Chalmers-Redman R, Tatton N (2003) Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm 110: 509-515
58. Temlett JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J Neurochem 62: 134-146
59. Thull U, Kneubuhler S, Gaillard P, Carrupt PA, Testa B, Altomare C, Carotti A, Jenner P, McNaught KS (1995) Inhibition of monoamine oxidase by isoquinoline derivatives. Qualitative and SD-quantitative structure-activity relationships. Biochem Pharmacol 50(6): 869-877
60. Tipton KF, Youdim MBH (1983) Assay of monoamine oxidases. In: Nagatsu T, Parvez H (eds) Research methods in catecholamines. North Holland, Amsterdam, pp 442-465
61. Tipton KF, McCrodden JM, Youdim MB (1986) Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP). Biochem J 240(2): 379-383
62. Warshawsky B, Ben Shachar D, Youdim MBH (2002) Pharmaceutical compositions comprizing iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International application published under the patent cooperation treaty. International Publication Number WO 00/74664 A2
63. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MBH (2002) The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16: 1674-1676
64. Yogev-Falach M, Amit T, Bar-Am O, Youdim MBH (2003) The importance of propargylamine moiety in the anti-parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J 17: 2325-2327
65. Youdim MBH (1975) Assay and purification of brain monoamine oxidase. In: Marks N, Rodnight R (eds) Methods in neurochemistry. Plenum Press, New York, pp 175-219
66. Youdim MBH (2003) Rasagiline. An anti-Parkinson drug with neuroprotective activity. Expert Rev Neurother 3(6): 737-749
67. Youdim MB (2003) What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease? J Neural Transm [Suppl 65]: 73-88
68. Youdim MBH, Sourkes TL (1965) The effect of heat, inhibitors and riboflavin deficiency on monoamine oxidase. Can J Biochem 43: 1305-1308
69. Youdim MBH, Riederer P (2004) Iron in the brain, normal and pathological. In: Adelman G, Smith BH (eds) Encyclopedia of neuroscience. Elsevier Science, Amsterdam, pp (in press)
70. Youdim MB, Banerjee DK, Keiner K, Offutt L, Pollard HB (1989) Steroid regulation of monoamine oxidase activity in the adrenal medulla. FASEB J 3(6): 1753-1759
71. Youdim MB, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord 8: 1-12
72. Youdim MBH, Grunblatt E, Mandel S (1999) The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann NY Acad Sci 890: 7-25
73. Youdim MBH, Gross A, Finberg JPM (2001a) Rasagiline [N-Propargyl-1R(+)- aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132: 500-506
74. Youdim MBH, Wadia A, Tatton NA, Weinstock M (2001b) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939: 450-458
75. Youdim MBH, Eshek G, Ben Shachar D (2004) Iron out iron in Parkinson's disease and other neurodegenerative diseases with iron chelators. A lesson from 6-hydroxydopamine and iron chelaros desferal and VK-28. Ann NY Acad Sci 1012: 306-326
76. Zheng H, Youdim MBH, Weiner LM, Bar-Am O, Cabantchik I, Warshawsky A, Fridkin M (2004) Design, synthesis and evaluation of novel iron-chelators as potential agents for treatment of neurodegenerative diseases with iron misregulation. J Med Chem (in press)